Cohen Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Cohen Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-652	Closed	-$22K	–	151
2020 Q3	$22K	Hold	652	–	–	0.01%	140
2020 Q2	$37K	Hold	652	–	–	0.01%	136
2020 Q1	$38K	Hold	652	–	–	0.01%	122
2019 Q4	$52K	Hold	652	–	–	0.01%	136
2019 Q3	$65K	Hold	652	–	–	0.01%	130
2019 Q2	$87K	Buy	+652	New	+$101K	0.02%	130

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cohen Capital Management's ONCT Position: Q4 2020 in Review

Cohen Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2020, closing a stake of 652 shares — an estimated $22K sold.

Cohen Capital Management first reported a position in ONCT in Q2 2019 and held it in 6 quarters. The position peaked at $87K in Q2 2019. 52 funds tracked by Wall St. Rank hold ONCT as of Q4 2020.

Cohen Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Cohen Capital Management sold 652 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $22K.
Cohen Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Cohen Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $87K in Q2 2019.
52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Cohen Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.